Today, Myriad Genetics (MYGN) disclosed that it, along with three other assignees (the University of Utah, the University of Pennsylvania and the Hospital for Sick Children, Endorecherche), had filed a patent infringement lawsuit in the United States District Court for the District of Utah against Ambry Genetics.
The suit alleges that Ambry violated up to ten patents owned or licensed by the patent owners relating to Myriad’s methods of testing for the BRCA1 and the BRCA2 gene mutations. As part of the lawsuit, the patent owners are seeking a preliminary injunction to prevent Ambry from selling services that use the intellectual property protected by the patents, including Ambry’s BRCAplus, BreastNext, OvaNext and CancerNext tests. The patent owners also are seeking damages up to threefold the amount of any profits lost as a result of a finding that Ambry’s infringement is willful.
Disclosure: I own shares of MYGN.
Disclaimer: The content on this site is provided for general educational and informational purposes only and should not be taken as investment advice. All site content, including advertisements, shall not be construed as a recommendation to buy or sell any security or financial instrument, or to participate in any particular trading or investment strategy. The ideas expressed on this site are solely the opinions of the author and do not necessarily represent the opinions of sponsors or firms affiliated with the author. Any action taken by you as a result of information, analysis, or advertisement provided on this site is ultimately your responsibility. Consult your investment adviser before making any investment decisions.
